Grundium Buys Visiopharm for AI Precision Pathology

Jan de Vries · 2026-05-25

### A Big Move in Digital Pathology Finland's Grundium, a startup that makes compact digital pathology scanners, just bought Denmark's Visiopharm, a company known for its AI-driven precision pathology software. This isn't just another acquisition—it's a strategic play to build an end-to-end platform for labs and researchers. Grundium is backed by EW Healthcare Partners, a US-based healthcare private equity firm. The combined company now offers both the hardware (scanners) and the software (AI analysis) needed for modern pathology work. That's a powerful combo. ### What This Means for Labs and Researchers For diagnostic labs, this merger is about convenience and capability. Instead of piecing together different tools from different vendors, labs can now get a complete solution from one source. That saves time and reduces headaches. "Precision medicine begins with precision pathology," said Mika Kuisma, CEO of Grundium. "By combining Grundium's imaging technologies with Visiopharm's advanced AI applications, we are creating a stronger foundation for physicians and laboratories to adopt high-value workflows and scale them over time." ### The Tech Behind the Deal Grundium was founded in 2015 by former Nokia engineers—Kimmo Alanen, Mika Kuisma, and Janne Haavisto. They developed the Ocus series of microscope scanners. These are compact, high-precision devices that make digital and remote pathology accessible to labs of any size. Visiopharm, founded in 2002 by Michael Grunkin and Johan Dore Hansen, focuses on AI-driven image analysis for pathology. They have nine diagnostic algorithms cleared under IVDR for EU customers. These algorithms help pathologists make faster, more accurate diagnoses. ### Key Benefits of the Combined Platform - **End-to-end workflow**: From scanning slides to analyzing them with AI, everything works together seamlessly. - **Lower costs**: Compact scanners remove infrastructure barriers, making digital pathology affordable for smaller labs. - **Scalability**: The platform supports everything from single-lab setups to enterprise-scale deployments. - **Continuity**: Both companies will continue supporting their existing products independently, so current customers aren't left in the lurch. ### What the Leaders Are Saying "Grundium and Visiopharm bring together highly complementary capabilities," said Michael Grunkin, CEO of Visiopharm. "This combination allows us to connect biomarker analysis, imaging, and quality management in new ways, while continuing to support the software and workflows our customers rely on today." Andy Thomson, Operating Partner at EW Healthcare Partners, added, "Digital pathology has the potential to drastically improve diagnostic accuracy, workflow efficiency, and global access to expert care. The platform we are creating brings these capabilities together to make diagnosis faster, more reliable, and more efficient." ### Looking Ahead This acquisition is more than just a business deal—it's a sign of where the industry is heading. Precision medicine relies on precise diagnostics, and that means having the right tools. By combining imaging hardware with AI software, Grundium and Visiopharm are positioning themselves to lead the next wave of digital pathology. For labs and researchers in the US and beyond, this means access to a more integrated, user-friendly platform. And that could translate into better patient outcomes, especially in areas like oncology where speed and accuracy matter most. Both companies had already worked together before this acquisition, integrating their solutions for labs. Now, with a formal merger, they're doubling down on that partnership. Expect to see more innovation from this combined team in the months ahead.